Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozone therapy in refractory ischemic heart disease and heart failure
2018-000201-24Phase 2Terminated
- Sponsor
- Hospital Universitario de Gran Canaria Dr. Negrín
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in coronary arteriosclerosis and chronic heart failure (CHF) comparing Standard of care + ozone therapy with Standard of care (control) (2 arms). Primary endpoint: Minnesota Living with Heart Failure questionnaire score. Started Jun 2018; status: terminated.
02
Drugs
medical ozonated water
03
Conditions
coronary arteriosclerosischronic heart failure (CHF)
Beyond the preview
Go deeper on 2018-000201-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000201-24.